Clinical Evidence

Proof of concept of randomized controlled study of Curcumin C3 Complex® as adjunct treatment in Schizophrenia: effects on negative and depressive symptoms
Cultivating Natural Bioactives: International Conference July 9 to 11, 2012
For the first time the study demonstrates the efficacy of Curcumin C3 Complex®, when combined with BioPerine® as a metabolic enhancer in schizophrenia and also highlights the significance of targeting epigenetics signal pathway in schizophrenia.
Study Design:

Authors designed a parallel group randomized trial (15 subjects) of schizophrenia with persisted negative symptoms.

Results and Discussion:

It was observed that both 1 g and 4 g Curcumin groups improved in their negative symptoms over 12 weeks. On the neurocognitive domain, the C-3 treated groups demonstrated positive change in overall neurocognitive index. Curcumin was highly tolerated with no serious adverse events.


Curcumin C3 Complex® is safe and active in improving the negative and depressive symptoms in schizophrenia.